Table 3.
The top 10 funding agencies contributed to targeted immunotherapy for MG.
| Rank | Funding agencies | Countries | Count | Percentage(N=824) | H-index |
|---|---|---|---|---|---|
| 1 | National Institutes of Health (NIH) | USA | 105 | 12.74 | 37 |
| 2 | United States Department of Health and Human Services (HHS) | USA | 105 | 12.74 | 37 |
| 3 | NIH National Institute of Neurological Disorders Stroke (NINDS) | USA | 56 | 6.80 | 25 |
| 4 | National Natural Science Foundation of China (NSFC) | China | 52 | 6.31 | 12 |
| 5 | European commission | Belgium | 43 | 5.22 | 21 |
| 6 | NIH National Institute of Allergy Infectious Diseases (NIAID) | USA | 31 | 3.76 | 20 |
| 7 | Association Francaise Contre Les Myopathies | France | 26 | 3.16 | 15 |
| 8 | Muscular Dystrophy Association | USA | 24 | 2.91 | 17 |
| 9 | Alexion Pharmaceuticals | USA | 16 | 1.94 | 9 |
| 10 | Ministry of Education, Culture, Sports, Science, and Technology (MEXT) | Japan | 14 | 1.70 | 8 |